Kwality Pharmaceuticals Ltd (KPL)

📊 Quarterly Results (₹ Cr)

Revenue has grown steadily from ₹111 crores (Sep 2025) to ₹162 crores (Jun 2026), with operating margins expanding from 18.4% to 22.2%, indicating improving operational efficiency. Net profit and EPS have risen consistently (₹14 cr → ₹26 cr), reflecting effective cost management and scale benefits. Despite oncology's revenue share decline, overall profitability trends remain positive, aligning with management's focus on margin expansion and operational discipline.

🔮 Management Outlook & What's Next

Management has provided forward-looking guidance of INR700+ crores revenue for FY27 with 26-27% EBITDA margins and long-term targets of INR1,500 crores revenue by FY30 with 30%+ EBITDA margins. They are prioritizing global market penetration, regulatory approvals in 70-80 countries, and strategic investments in R&D (e.g., Erythropoietin trials) to drive sustainable growth and higher margins, while addressing working capital and margin pressures through operational improvements.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows consistent growth in equity and reserves (₹280 cr to ₹321 cr) alongside controlled borrowing increases (₹110 cr to ₹130 cr), indicating disciplined capital allocation. Total assets grew from ₹447 cr to ₹592 cr, reflecting operational expansion without excessive leverage. The company is reinvesting profits to fund growth while maintaining a conservative debt profile, supporting its long-term international expansion strategy.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at ~54.86%, signaling confidence in long-term prospects. Institutional ownership (FII/DII) has modestly increased (FII: 0% → 3.13%, DII: 0.33% → 0.56%), suggesting growing institutional interest. The rising number of shareholders (10,555 → 13,279) indicates broadening retail and institutional participation, reflecting positive market sentiment and potential for wider analyst coverage.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) Oncology revenue decline to 20% (from 26%) raises concerns about execution of growth strategy in key therapeutic areas. 2) Margin pressure is being actively managed but remains a focus area amid global expansion and R&D investments. 3) Dependence on international regulatory approvals and market acceptance introduces execution risk in new geographies. 4) Working capital management improvements are critical to sustain cash flow generation during the growth phase.

📋 Recent Filings

• Announcement2026-09-28Kwality Pharmaceuticals Ltd announced that its trading window will close on October 1, 2026, remaining shut for 48 hours after the unaudited financial…
• 🟡 voting results2026-09-02Kwality Pharmaceuticals Limited held its 43rd Annual General Meeting on August 31, 2026, where shareholders approved all six resolutions including the…
• 🟡 Board Meeting2026-09-02Kwality Pharmaceuticals announced at its August 31, 2026 AGM the regularization of Mr. Swanith Kapoor’s appointment as Non-Executive Independent Direc…
• 🟡 Board Meeting2026-08-31Kwality Pharmaceuticals held its 43rd AGM on August 31, 2026 via video conference, with all directors present and 34 shareholders attending. The meeti…
• 🟡 concall transcript2026-06-30Kwality Pharmaceuticals reported Q1 FY27 results with oncology revenue at 20% of total, down from 26%, and reaffirmed FY27 revenue guidance of INR700+…
• 🟡 concall transcript2026-03-31Kwality Pharmaceuticals reported FY26 revenue of INR503 crores (up 36% YoY) and PAT of INR67 crores (up 69%), with margins expanding to 13.4% from 10.…

🧠 Analyst's Read

Kwality Pharmaceuticals is executing a clear strategic shift toward global specialty pharma with strong financial fundamentals and disciplined growth targets. Investors should monitor oncology performance trends, progress in international registrations, and execution of margin improvement initiatives, particularly as Erythropoietin trials commence and new product launches gain traction.

Based on filing content and financial data. Not a recommendation.